These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

71 related items for PubMed ID: 4334860

  • 21. Pyrimidine-specific antibodies: reaction with DNA's of differing base compositions.
    Garro AJ, Erlanger BF, Beiser SM.
    J Immunol; 1971 Feb; 106(2):442-9. PubMed ID: 4322722
    [No Abstract] [Full Text] [Related]

  • 22. [Isolation and study of the serological properties of cell wall components of Clostridium perfringens type A].
    Ispolatovskaia MV, Shaposhnikova GM, Zemlianitskaia EP.
    Zh Mikrobiol Epidemiol Immunobiol; 1973 Feb; 50(2):40-4. PubMed ID: 4131793
    [No Abstract] [Full Text] [Related]

  • 23. [Factors modulating production of antibodies against Clostridium perfringens in mammals].
    Shemanova GF, Sergeeva TI, Panteleev EI, Vlasova EV, Dmitrieva LN.
    Biull Eksp Biol Med; 1981 Sep; 92(9):322-5. PubMed ID: 6271303
    [Abstract] [Full Text] [Related]

  • 24. Immunity to Hemophilus influenzae type b. I. The isolation, and some physicochemical, serologic and biologic properties of the capsular polysaccharide of Hemophilus influenzae type b.
    Rodrigues LP, Schneerson R, Robbins JB.
    J Immunol; 1971 Oct; 107(4):1071-80. PubMed ID: 4999258
    [No Abstract] [Full Text] [Related]

  • 25. The detection of the factor lowering the immunogenicity of toxoid of Clostridium perfringens type A.
    Shemanova GF, Vlasova EV, Sergeeva TI, Panteleyev EI.
    Arch Roum Pathol Exp Microbiol; 1981 Oct; 40(4):299-303. PubMed ID: 6280638
    [No Abstract] [Full Text] [Related]

  • 26. [Comparative evaluation of the methods of determining perfringens A antitoxin].
    Shemanova GF, Trapezov EV, Musina EE, Vlasova EV, Panteleev EI.
    Biull Eksp Biol Med; 1983 Nov; 96(11):82-4. PubMed ID: 6315110
    [Abstract] [Full Text] [Related]

  • 27. Development of monoclonal antibodies suitable for use in antigen quantification potency tests for clostridial veterinary vaccines.
    Hauer PJ, Clough NE.
    Dev Biol Stand; 1999 Nov; 101():85-94. PubMed ID: 10566780
    [Abstract] [Full Text] [Related]

  • 28. [Allergy of enteroflora--cross-reactivities between Clostridium perfringens and the organs].
    Ito N.
    Arerugi; 1969 Sep; 18(9):775-91. PubMed ID: 4311581
    [No Abstract] [Full Text] [Related]

  • 29. Beta toxin is essential for the intestinal virulence of Clostridium perfringens type C disease isolate CN3685 in a rabbit ileal loop model.
    Sayeed S, Uzal FA, Fisher DJ, Saputo J, Vidal JE, Chen Y, Gupta P, Rood JI, McClane BA.
    Mol Microbiol; 2008 Jan; 67(1):15-30. PubMed ID: 18078439
    [Abstract] [Full Text] [Related]

  • 30. THE POLYSACCHARIDES OF CLOSTRIDIUM PERFRINGENS.
    MEISEL-MIKOLAJCZYK F.
    Arch Immunol Ther Exp (Warsz); 1963 Jan; 11():313-40. PubMed ID: 14059310
    [No Abstract] [Full Text] [Related]

  • 31. [The toxins of Clostridium perfringens type C].
    Nedialkov S, Peichev B.
    Vet Med Nauki; 1974 Jan; 11(2):73-8. PubMed ID: 4370604
    [No Abstract] [Full Text] [Related]

  • 32. Immunochemistry of the capsular polysaccharides from Clostridium perfringens: selected Hobbs strains 1, 5, 9, and 10.
    Cherniak R, Henderson BG.
    Infect Immun; 1972 Jul; 6(1):32-7. PubMed ID: 4343932
    [Abstract] [Full Text] [Related]

  • 33. Properties of antisera to ganglioside GM1 and asialo GM1.
    Naiki M, Marcus DM, Ledeen R.
    J Immunol; 1974 Jul; 113(1):84-93. PubMed ID: 4364954
    [No Abstract] [Full Text] [Related]

  • 34. [Production, purification and characterization of some Clostridium perfringens toxins].
    Capunzo M, Mariano A, Cavallo R.
    G Batteriol Virol Immunol; 1982 Jul; 75(1-6):48-61. PubMed ID: 6315516
    [Abstract] [Full Text] [Related]

  • 35. Clostridium perfringens exotoxins. II. Purification and some properties of theta-toxin.
    Mitsui K, Mitsui N, Hase J.
    Jpn J Exp Med; 1973 Oct; 43(5):377-91. PubMed ID: 4359556
    [No Abstract] [Full Text] [Related]

  • 36. Immunochemical studies on chlamydial group antigen (presence of a 2-keto-3-deoxycarbohydrate as immunodominant group).
    Dhir SP, Hakomori S, Kenny GE, Grayston JT.
    J Immunol; 1972 Jul; 109(1):116-22. PubMed ID: 4338437
    [No Abstract] [Full Text] [Related]

  • 37. Common polysaccharide antigens from the cell envelope of Clostridium perfringens type A.
    Dayalu KI, Cherniak R, Hatheway CL.
    Infect Immun; 1981 Feb; 31(2):608-14. PubMed ID: 6260671
    [Abstract] [Full Text] [Related]

  • 38. Immunochemical studies on Shigella flexneri polysaccharides.
    Pogonowska-Goldhar J, Rdultowska H.
    Arch Immunol Ther Exp (Warsz); 1967 Feb; 15(2):176-90. PubMed ID: 6050439
    [No Abstract] [Full Text] [Related]

  • 39. Analysis of protection afforded by a Clostridium perfringens alpha-toxoid against heterologous clostridial phospholipases C.
    Neeson BN, Clark GC, Atkins HS, Lingard B, Titball RW.
    Microb Pathog; 2007 Oct; 43(4):161-5. PubMed ID: 17604945
    [Abstract] [Full Text] [Related]

  • 40. Clostridium perfringens vaccines.
    Titball RW.
    Vaccine; 2009 Nov 05; 27 Suppl 4():D44-7. PubMed ID: 19837285
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.